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1025-64 Long-Term Clinical Outcome of Catheter-Based 
Intramyocardial Autologous Bone Marrow Cells 
Implantation in Patients With End-Stage Coronary 
Artery Disease
Hung-Fat Tse, Sukumaran Thambar, Yok-Lam Kwong, John KF Chan, Gladys Lo, Chi-Lai 
Ho, Wai-Hong Chen, Grey Bellan, Chu-Pak Lau, University of Hong Kong, Queen Mary 
Hospital, Hong Kong, Hong Kong, Hunter Heart-Lung Research Guild, John Hunter 
Hospital, Newcastle, Australia
Background: Recent experimental studies have demonstrated bone marrow cell (BMC)
implantation induces neovascularization and improves heart function after myocardial inf-
arction. Despite enthusiasm for these pioneering clinical trials, the long-term safety and
efficacy of implanting autologous BMCs into the human myocardium remains a major
concern. The purpose of this study was to evaluate the long-term clinical outcome of
implanting autologous BMCs into patients (pts) with end-staged coronary artery disease
(CAD). Methods: We evaluated the long-term clinical outcome in 12 pts (mean age:
60±10 yrs, 11 males) with end-staged CAD who underwent catheter-based autologous
BMC cells implantation guided by electromechanical mapping. A mean of 1.1±0.2 ml of
mononuclear cells (106 cells/ ml, 2.9±2.6% of CD34+ cells) was injected to 16 ischemic
regions. No elevation in cardiac enzyme or pericardial effusion observed after the proce-
dure. 2 pts died of stroke (8 mths) and myocardial infarction (20 mths), respectively. After
23±6 mths follow-up, there were significant improvement in NYHA class (2.1±0.8 vs
2.8±0.5), angina class (2±0.9 vs 3.3±0.5) and quality of life (SF-36: 65±14 vs 51±15)
compared to baseline (all p<0.05). Stress SPECT-sestamibi studies demonstrated signif-
icant improvement in myocardial perfusion in 9/12 (75%) pts at 6 mths. Magnetic reso-
nance imaging at baseline, 3 and 6 mths after procedure showed no evidence of
intramyocardial tumor formation, myocardial damage or change in left ventricular function
(58±9 vs 59±11 vs 58±16%, p>0.05). Furthermore, no patient developed symptomatic
ventricular tachyarrhythmias nor detected by 24 hrs Holter at 3 and 6 mths follow-up.
Conclusions: Our study demonstrate that BMC implantation using a percutaneous cath-
eter procedure is safe and feasible in pts with “end-staged” CAD and improve their symp-
toms and quality of life. The absence of any acute procedural complications or long-term
sequalae, including ventricular arrhythmia, myocardial damage or development of
intramyocardial tumor, are encouraging in terms of the safety and feasibility of this novel
catheter-based cellular transplantation procedure for severe CAD.
1025-65 First Human Heart Myoblast Allograft
Peter Law, Cell Transplants International, LLC, Memphis, TN
Background
Endomyocardial myoblast injections deposited myofilaments and augmented contractility.
We report here the world’s first myoblast allografts into two CAD patients.
Methods
Quadriceps biopsy (2.18g) from a 20-year-old, pathogen-free male was cultured comply-
ing cGMP/ISO 9001 to yield 3.64x109 myoblasts that were 98.3% pure (desmin immuno-
positive), 91.5% viable, potent in myotube formation, and negative for endotoxin, myco-
plasma, sterility, and gram stain. Male subjects, aged 63 and 49, developed atherosclero-
sis, coronary artery disease, chronic myocardial infarction, stable angina Functional
Class IV (CCS), and arterial hypertension II (risk 4). PET with 18FDG revealed scars with
hibernated myocardium in LV septal, apical, and anterior/posterior wall regions. Echocar-
diography showed regional akinesis/hypokinesis, LVEF being 41% and 38%. On 1/17/
2003, they received 18/19 injections and 1.1/1.2 billion myoblasts (108 /mL), respectively.
The 0.5 mL injections were placed between infarcted and viable myocardium after CABG
on ice-chilled, non-beating hearts. Subjects took oral cyclosporine (5 to 7 mg/kg body
weight per day) for 8 weeks. Doses were adjusted to maintain whole blood trough level at
about 250 ng/mL. 24-hour Holter EKG was monitored.
Results
The subjects recovered with no rash or high fever. Both developed arrhythmia and extra-
systoles that were eliminated with Amiodarone. Rejection symptom was not observed
despite cyclosporine discontinuation. Between 3 to 8-months follow-up, both were in sta-
ble condition with angina at Class I-II. Echocardiography showed 14.6% and 10.5%
increases in LVEF with no local hypokinesis. SPECT with 30 mCi 99mTc-tetrophosphomin
demonstrated positive dynamics, LVEF increases, and reduction in perfusion defect
areas during exercise and rest. 18FDG accumulation was equable throughout LV myocar-
dium; glucose metabolism sustained.
Conclusions
The feasibility and preliminary safety/efficacy shown in these allografts provide a new
potential therapy for heart failure and its prevention, with virtually unlimited cell availability
and 2-month immunosuppression.
1025-66 Biological Markers of the Restenosis
Laurent Payot, Gilles Montalescot, Rémi Choussat, Michel Slama, Jean-Luc Dubois 
Randé, Jean-Philippe Metzger, J. Thillet, C. Bal, L. Drouet, Centre Hospitalier 
Universitaire Pitié-Salpétrière (AP-HP), Paris, France
Background:
The incidence of coronary restenosis 6 months following angioplasty is 25 to 45%
according to selected definitions. The detection of restenosis by non-invasive means
remain particularly disappointing. The purpose of this study was to evaluate the evolution
of potential biological markers of restenosis after angioplasty and identify whether some
are predictive of restenosis.
Methods and Results:
A total of 229 consecutive patients with chronic stable angina or stabilised unstable
angina, were recruited in five centers. Measurements of fibrinogen, CRP, tPA Ag, VWfAg,
f PAI-1
f VIIc, f VIIa, f VII Ag, TAT, D-Dimer, Ceruloplasmine, lipoprotein(a) were performed in a
central laboratory before and immediately after, two months, four months and six months
after angioplasty. The criterion of evaluation was restenosis defined clinically and angio-
graphically. A systematic clinical and angiographic follow-up was obtained in all patients.
The relations between biological variables and definitions of restenosis were assessed
by univariate and multivariate analyses. A prolonged elevation of CRP and fibrinogen
was observed over the first four months of follow-up with some decrease at two month
and re ascension at four months( 32% increase of CRP between the second and fourth
month p=0.11; 4% increase of the fibrinogen, p=0.0022).A similar evolution was
observed for the plasma levels of f VIIc, f VII a, f VII Ag, f PAI. All the variables return to
baseline levels at six months. These biological profiles are consistent with the restenosis
process which occurs mainly between 2 and 4 months. However, after multivariate analy-
sis, no biological variable was significantly and consistently (with regards to the various
definitions) associated with restenosis, at any time point.
Conclusion: Ours findings suggest that inflammation occurs and can persist for 4 months
after angioplasty but no biological variable was found to be independently predictive of
clinical and/or angiographic restenosis.
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1026-55 In Vitro Detection and Quantification of High Intensity 
Transient Signals by Using Intracoronary Doppler 
Ultrasound: A New Approach to Detect Coronary 
Microembolization
Philipp Bahrmann, Marcel Wagner, Jens Hopfe, Markus Ferrari, Andreas Voss, Gerald S. 
Werner, Hans R. Figulla, Friedrich-Schiller-University, Jena, Germany, University of 
Applied Sciences, Jena, Germany
Introduction: Brief, high-intensity transient signals (HITS) in the Doppler velocity spec-
trum correspond to microemboli made of thrombotic and non-thrombotic material in labo-
ratory models. Transcranial doppler detection of HITS in the cerebral circulation was the
first clinical application to study the pathogenesis of embolism in humans. We used a
commercially available Doppler ultrasound device dedicated for the use in coronary arter-
ies for the validation of HITS detection in an in vitro model using artificial embolic parti-
cles.
Methods and Results: HITS were defined by the following characteristics: (1) high-
intensity signal, (2) short duration, (3) unidirectional within the Doppler velocity spectrum
and (4) accompanied by a "snap", "chirp" or "moan" on the audio output. An experimental
flow circuit was made of a polyethylene tube with an internal diameter of 3 mm. A flow
pattern similar to a human coronary artery was obtained by a roller pump. We positioned
a 0.014'' guidewire with a 12 MHz pulsed Doppler ultrasound transducer mounted on its
tip into the circuit. The guidewire was connected to a console (FloWire/FloMap System®,
Endosonics) that employed a 128-point fast Fourier transform for signal intensity mea-
